Market Intelligence on Biosimilar Therapeutic Peptides Industry 2025 – For Corporate Strategy and Innovation
Unlock 30% off global market reports with code ONLINE30 – get insights on tariff changes, macro trends, and global economic shifts.
What is the expected value of the biosimilar therapeutic peptides market over the forecast period?
The biosimilar therapeutic peptides market size has grown exponentially in recent years. It will grow from $2.06 billion in 2024 to $2.68 billion in 2025 at a compound annual growth rate (CAGR) of 30.3%. The growth in the historic period can be attributed to increasing demand for cost-effective therapeutics, regulatory support and frameworks, patent expirations of biologic drugs, rising incidence of chronic diseases, and established manufacturing processes.
The biosimilar therapeutic peptides market size is expected to see rapid growth in the next few years. It will grow to $4.87 billion in 2029 at a compound annual growth rate (CAGR) of 16.1%. The growth in the forecast period can be attributed to expanding therapeutic applications, the global aging population, market competitiveness, strategic collaborations and partnerships, and patient preference for non-invasive therapies. Major trends in the forecast period include advancements in biotechnology, increasing demand for biologics, technological innovations in manufacturing, focus on cost-efficiency and access to healthcare, and technological advancements.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3423&type=smp
What industry dynamics are acting as key growth drivers for the biosimilar therapeutic peptides market?
The increasing aging population is projected to surge the number of patients with chronic diseases, contributing to the biosimilar therapeutic peptides market's growth. Elderly people are more prone to various chronic diseases, which are surging the old age population rapidly across the world and is predicted to continue over the forecast period. According to the World Health Organization (WHO), the world’s population over the age of 60 is expected to reach 2 billion by the end of 2050. Moreover, according to the World Population Prospects, the number of people aged 80 and above is likely to increase from 143 million in 2019 to 426 million in 2050. Biosimilar therapeutic peptides are used for the treatment of various chronic diseases and cancers. The expected increase in the ageing population suffering from various chronic conditions will drive the growth of biosimilar therapeutic peptide market.
What are the fastest-growing segments in the biosimilar therapeutic peptides market forecast period?
The biosimilar therapeutic peptides market covered in this report is segmented –
1) By Type: Innovative, Generic
2) By Route Of Administration: Parenteral Route, Transdermal Route, Other Route Of Administrations
3) By Application: Cancer, Cardiovascular, Central Nervous Systems, Metabolic Disorders, Infection, Hematological Disorders, Gastrointestinal Disorders, Dermatology, Respiratory Disorders
Subsegments:
1) By Innovative: Long-Acting Peptides, Combination Peptides
2) By Generic: Monoclonal Antibodies, Hormones, Enzymes
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/biosimilar-therapeutic-peptide-global-market-report
What are the most notable trends influencing investment in the biosimilar therapeutic peptides sector?
Major companies in the biosimilar therapeutic peptide market are developing a research platform for optimizing peptide synthesis, enhancing production efficiency, and ensuring consistent quality, from discovery to commercialization. Biodrug Design Accelerator, a platform to manage research processes for peptide drug discovery, which many regard as a promising frontier in the field of new drug development. For instance, in May 2023, Fujitsu Limited, a US-based toy manufacturing and entertainment company, launched the Biodrug Design Accelerator platform to accelerate peptide drug discovery research. Biodrug Design Accelerator will support peptide drug discovery scientists in pharmaceutical companies to accelerate and improve the efficiency of peptide drug development, specifically through the cycles design, make, test, analyze (DMTA), ultimately enabling accelerated and informed design of peptide drug candidates as well as efficient communication among scientists regarding synthesis and testing.
Which major players hold significant market share in the biosimilar therapeutic peptides sector?
Major companies operating in the biosimilar therapeutic peptides market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceuticals Co. Ltd., Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, BioXpress Therapeutics SA, Apotex Inc., Teva Pharmaceuticals Industries Ltd., Sandoz International GmbH, Lonza Inc., Stada Arzneimittel AG, Ipsen S.A, Biocon Biopharmaceuticals Pvt. Ltd., Dr. Reddy's Laboratories Ltd., Alvogen Pharma US Inc., Corden Pharma GmbH, Bachem Holding AG, PolyPeptide Laboratories Ltd., PeptiDream Inc., Coherus BioSciences Inc., Celltrion Inc., BioPartners Inc., Samsung Bioepis Co. Ltd.
Which regional segments are forecasted to witness the fastest growth in the biosimilar therapeutic peptides market?
The countries covered in the biosimilar therapeutic peptides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
How Can Companies Use The Biosimilar Therapeutic Peptides Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3423
Need Customized Data On Biosimilar Therapeutic Peptides Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you're entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=3423&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment